Novel anti-tslp antibodies

The antibody or antigen-binding fragment thereof of any of the preceding claims, comprising a heavy chain variable region (VH) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:

• 1, 3, 5, 7, 8, 10 and 86, or a homologous sequence thereof having at least 80% sequence identity.

The antibody or antigen-binding fragment thereof of any of the preceding claims, comprising a light chain variable region (VL) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:

• 2, 4, 6 and 9, or a homologous sequence thereof having at least 80% sequence identity.

The antibody or an antigen-binding fragment thereof of any of the preceding claims, wherein at least one of the substitutions or modifications is in one or more of the complementary determining region (CDR) sequences of the heavy chain variable region or light chain variable region.

The antibody or an antigen-binding fragment thereof of any of the preceding claims, wherein at least one of the substitutions or modifications is in one or more of the non-CDR sequences of the heavy chain variable region or light chain variable region.

The antibody or an antigen-binding fragment thereof of any one of the preceding claims, further comprising an Fc region, optionally an Fc region of human immunoglobulin (Ig), or optionally an Fc region of human IgG.

The antibody or antigen-binding fragment thereof of any of the preceding claims, further comprising a signal peptide at the N-terminal of the heavy chain variable region and/or a signal peptide at the N-terminal of the light chain variable region.

The antibody or an antigen-binding fragment thereof of any one of the preceding claims, which is humanized.

The antibody or an antigen-binding fragment thereof of any one of the preceding claims, which is a monoclonal antibody, a bispecific antibody, a multi-specific antibody, a recombinant antibody, a chimeric antibody, a labeled antibody, a bivalent antibody, an anti-idiotypic antibody or a fusion protein.

The antibody or an antigen-binding fragment thereof of any one of the preceding claims, which is a diabody, a Fab, a Fab′, a F(ab′)2, a Fd, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a bispecific dsFv (dsFv-dsFv′), a disulfide stabilized diabody (ds diabody), a single-chain antibody molecule (scFv), an scFv dimer (bivalent diabody), a multispecific antibody, a camelized single domain antibody, a nanobody, a domain antibody, or a bivalent domain antibody.

The antibody or antigen-binding fragment thereof of any of the preceding claims, further comprising one or more amino acid residue substitutions or modifications yet retains binding specificity to human TSLP.

The antibody or an antigen-binding fragment thereof of any one of the preceding claims, binding to a different epitope from what a reference antibody binds, wherein the amino acid sequence of the heavy chain of reference antibody is shown as SEQ ID NO:

• 77, and the amino acid sequence of the light chain of reference antibody is shown as SEQ ID NO:
• 78.

The antibody or an antigen-binding fragment thereof of any one of the preceding claims, which is linked to one or more conjugate moieties.

A method of treating, preventing or alleviating a TSLP-related disease or disorder in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof capable of binding to long-form human TSLP having an amino acid sequence as shown in SEQ ID NO:

• 73, and a digested form of TSLP.